key: cord-0921129-qaauuls2
authors: Pardamean, Engelberta; Roan, Waskita; Iskandar, Karina Terry Amartini; Prayangga, Regina; Hariyanto, Timotius Ivan
title: Mortality from coronavirus disease 2019 (Covid-19) in patients with schizophrenia: A systematic review, meta-analysis and meta-regression
date: 2022-02-04
journal: Gen Hosp Psychiatry
DOI: 10.1016/j.genhosppsych.2022.01.010
sha: 2827bfa97d8f1d84a6f2d209023a038a170722ef
doc_id: 921129
cord_uid: qaauuls2

OBJECTIVE: Schizophrenia has been associated with patients' poor quality of life, disability, and hospitalization. As of today, evidence that highlights the association between schizophrenia and coronavirus disease (Covid-19) outcomes remains unclear. This study sought to analyze whether patients with pre-existing schizophrenia are at higher risk for Covid-19 mortality. METHODS: Using specific keywords, we comprehensively searched PubMed, Scopus, OVID, and Cochrane Library sources until November 15th, 2021. All published studies on schizophrenia and Covid-19 were collected. We used Review Manager 5.4 and Comprehensive Meta-Analysis 3 software to conduct statistical analysis. RESULTS: There were 10 studies with 263,207 Covid-19 patients included in the analysis. Evaluation of the data gathered yielded an association between schizophrenia and increased mortality from Covid-19 (RR 2.22; 95%CI: 1.54–3.20, p < 0.00001, I(2) = 82% random-effect model). The increased risk of developing mortality from Covid-19 in patients with schizophrenia was significantly influenced by older age (p = 0.0004) and smoking (p = 0.0048). CONCLUSIONS: This study proposes that patients with pre-existing schizophrenia are at risk of developing higher Covid-19 mortality. Patients with schizophrenia need special attention and should be prioritized to receive the SARS-CoV-2 vaccine. Registration details: CRD42021293997.

The worldwide pandemic of Covid-19 has been ongoing since early 2020, however the transmission and death rate are constantly increasing, thus it is still considered a major global challenge. As of November 2021, COVID-19 cases exceeded 250 million, with more than 5 million deaths worldwide. [1] While some patients with SARS-CoV-2 may develop mild nondebilitating self-limiting upper-respiratory symptoms, a significant percentage of patients may also develop destructive and progressive symptoms that require hospitalizations and intensive care treatment due to the threat of symptoms progression into acute respiratory distress syndrome (ARDS) and multi-organ failure. [2] [3] [4] Thus, Covid-19 remains a great threat to the global healthcare system, especially in vulnerable populations with established risk factors including older age, unhealthy lifestyle, physical comorbidities, and psychiatric illnesses. [5] [6] [7] [8] [9] [10] Previously published studies have tended to focus on the general medical (e.g.,

Four databases were searched systematically for English-language articles (PubMed, Scopus, OVID, and the Cochrane Library). Keywords such as "(Covid-19 OR SARS-CoV-2 OR 2019-nCoV OR Severe acute respiratory syndrome coronavirus 2) AND (mortality OR death OR association) AND (pre-existing OR pre-existent OR pre-pandemic OR prior) AND (schizophrenia OR schizophrenic OR psychosis OR mental illness OR mental disorder OR psychiatric) NOT (psychosocial OR social OR social distancing OR lockdown OR quarantine OR sequelae)" were used to filter the intended studies from the period of 2019 until November 15 th , 2021. The sample search strategies used in this study are provided in Supplementary Table   1 . The initial step was the identification of eligible articles through screening of titles and abstracts by two reviewers. Additional evaluation of references from found eligible studies were also conducted to search for more potential articles. Duplicate articles were removed. Finally, full-text articles were independently screened by 2 reviewers, with discrepancies resolved through discussion. Meta-analysis of Observational Studies in Epidemiology (MOOSE) [16] and Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines were employed for our study. [17] Begg and Mazumdar's rank correlation method was used to assess the quantitative risk of publication bias. [19] 3. RESULTS

The initial database search yielded 334 studies, from which 30 were eligible after screening titles and abstracts and removal of duplicates. Of these eligible studies, 20 articles were further excluded after full-text screening. Seven articles did not contain relevant and/or complete data for the specified outcome measures, five articles did not contain discrete data for schizophrenia, five articles did not use a valid mode of ascertainment for schizophrenia or only included schizophrenia symptoms, three articles were not primary research thus resulting in the final number of 10 studies [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] which included a total of 263,207 Covid-19 patients for the analysis ( Figure 1 ). Out of 10 studies, seven were retrospective cohort, two were case-control studies, and the remaining one article was prospective cohort. Sample sizes ranged from 87 to 144,321. Most of the included studies used ICD-10 criteria for the diagnosis of schizophrenia and RT-PCR method for the diagnosis of Covid-19. Table 1 provides details regarding the included studies.

The NOS scale was used to evaluate the quality of cohort and case-control studies, which indicated all included studies had good quality ( Table 2 ). All studies were deemed fit to be included in the meta-analysis.

J o u r n a l P r e -p r o o f Journal Pre-proof

The pooled estimate indicated that the risk of mortality from Covid-19 was significantly higher for individuals with pre-existing schizophrenia when compared with those without schizophrenia (RR 2.22; 95%CI: 1.54 -3.20, p<0.00001, random-effect model) ( Figure 2 ). The meta-analysis for Covid-19 mortality exhibited a high degree and considerable heterogeneity (I 2 = 82%).

Meta-regression was performed to identify risk factors which influence the relationship between schizophrenia and mortality from Covid-19. Our meta-regression revealed that variability in mortality from Covid-19 in patients with schizophrenia was explained by known patient factors associated with predictors of Covid-19 outcome (Supplementary Table 2 

We used Funnel plot analysis for the mortality from Covid-19 outcome (Supplementary Figure 2) . This analysis showed a relatively symmetrical inverted-plot, indicating no publication J o u r n a l P r e -p r o o f Journal Pre-proof underdiagnosis and unoptimized treatment given by the clinicians, mortality could also increase due to the fact that these patients did not adhere well to their given treatments, leading to a more fatal outcome. [15] A second possible explanation for increased mortality in patients with schizophrenia could be reduced vaccination rates. In an Israeli study, only 50.6% of patients with schizophrenia were vaccinated, compared to 52.8% in the comparison group. [21] However, vaccinated patients with schizophrenia had reduced hospitalizations and mortality. [21, 32] Thus, results from that study and the current meta-analysis demonstrate the importance of prioritizing Covid-19 vaccination in patients with schizophrenia.

Third, people with schizophrenia may have susceptibility because of immune system dysregulation. Various lines of research, including genome-wide association studies, suggest dissimilarity in HLA (major histocompatibility complex) proteins and deficient T-cell mediated immune responses in patients with schizophrenia. [33] This immune system dysregulation in patients with schizophrenia was evident in the context of Covid-19 infection, in which these patients typically presented with higher levels of inflammatory biomarkers, cytokines, and chemokines, such as procalcitonin, serum ferritin, erythrocyte sedimentation rate, IL-1β, IL-2R, IL-6, IL-8, IL-10, TNF-α, GDF-15, and CRP. [34] [35] [36] The increase of these substances would lead to a systemic proinflammatory state and eventually cause a cytokine storm that may result in more critical symptoms, multi-organ failure, and even death. [37] [38] [39] Apart from proinflammatory cytokines, the fourth possible explanation for the increased mortality rate of schizophrenic patients from Covid-19 is the disrupted modulation of the impairment that lead to fatal thromboembolic events. [36, 40] This theory was supported by a study in China that reported higher levels of D-dimer in the non-survivor group compared to the survivor group (p < 0.0001), thus demonstrating a significant association of hypercoagulability state and death in patients with COVID-19. [38] These findings were then linked to evidence of hypercoagulability in schizophrenic patients. In several studies, patients with mental illness, including schizophrenia, had higher concentrations of D-dimer level (with a median value of 2061 ng/mL, according to a study conducted in New York City community hospital) as well as plasminogen activator inhibitor (PAI-1) compared to controls, which made them more susceptible to thrombotic complications. [41] Patients with schizophrenia were also reported to have 3 times the risk for deep vein thrombosis and 2.6 times the risk for pulmonary embolism. [42] Our results would fit with the possibility of a hypercoagulable state in patients with schizophrenia additionally affected with Covid-19, leading to thromboembolism and death.

Several risk factors for thromboembolic events are common in patients with schizophrenia.

These risk factors include smoking rate which is higher among patients with psychiatric conditions; metabolic syndrome caused by illness and treatment (with a higher risk in low potency antipsychotics (AOR 20.8 (95% CI: 1.7-259.0))); unhealthy lifestyle affected by illness and the use of physical restraint. [42, 43] Fifth, it is possible that antipsychotic medications could interfere with the coagulation cascade, through a variety of mechanisms. For example, antipsychotic adverse effects could lead to thromboembolism through sedation, obesity, enhanced platelet aggregation, increased antiphospholipid antibodies, and hyperprolactinemia. [44] Prolactin is a platelet aggregation coactivator, and its release is inhibited by dopamine. As several antipsychotics are dopamine D2-J o u r n a l P r e -p r o o f receptor antagonists, repressed secretion of dopamine would lead to the increase of prolactin. [44] Other than causing thromboembolism, antipsychotic drugs such as clozapine, risperidone, and haloperidol could also worsen the clinical outcome of Covid-19 by increasing the susceptibility to infections. According to research, clozapine increased infection vulnerability through increasing agranulocytosis and blood dyscrasia, while risperidone increased global immunosuppression, and haloperidol increased the risk of acute respiratory failure in patients with schizophrenia and COPD. [34] Given these considerations, clinicians should take care when prescribing antipsychotics to patients with active Covid-19 infection.

Lastly, comorbid illnesses in patients with schizophrenia could influence the pathophysiology and morbidity/mortality of Covid-19 infection. Common medical conditions found in patients with mental illness include glucose-regulation abnormalities, insulin resistance, type 2 diabetes mellitus, hyperlipidemia, hypertension, cardiac arrhythmias, obesity, malignant neoplasms, HIV/AIDS, hepatitis C, osteoporosis, hyperprolactinemia, irritable bowel syndrome, and Helicobacter pylori infection. [45] [46] [47] [48] These conditions are associated with the use of antipsychotic medications, lifestyle factors, and inability to adapt to healthier lifestyles. [49] Higher mortality has been observed in patients with Covid-19 and certain risk factors, such as older age, male sex, pre-existing hypertension, diabetes, coronary heart disease, and chronic kidney disease. [37, 49] The risk of comorbid conditions appears particularly high among patients younger than 50 years old. [50] Thus it can be concluded that patients with schizophrenia and preexisting comorbidities are susceptible to mortality from Covid-19. Finally, in some of the included studies, it is not possible to determine whether Covid-19 was the underlying cause of death or not, therefore some of the deaths in these studies may be with Covid-19 rather than due to Covid-19. However, since this limitation also applies to the control group, we can assume null bias regarding this point.

In conclusion, our study suggests that patients with schizophrenia are at increased risk of death from Covid-19. This may be due to comorbid conditions, immune response dysregulation, hypercoagulability, antipsychotic use, and lack of vaccination. Clinicians should prioritize patients with schizophrenia for Covid-19 vaccines. In patients with schizophrenia who have Covid-19, clinicians should screen for hypercoagulability and take precautions when prescribing antipsychotics.

J o u r n a l P r e -p r o o f J o u r n a l P r e -p r o o f Barcella CA et al. [20] 2021 Cohort *** ** *** 8 Good

Bitan DT et al. [21] 2021 Cohort *** ** ** 7 Good

Fond G et al. [22] 2021 (a) Case-control *** ** ** 7 Good

Fond G et al. [23] 2021 (b) Cohort *** ** *** 8 Good

Jeon HL et al. [24] 2021 Cohort *** ** *** 8 Good

Nemani K et al. [25] 2021 Cohort *** ** *** J o u r n a l P r e -p r o o f

World Health Organization. Coronavirus disease (COVID-19): situation report

Anosmia/Hyposmia is a Good Predictor of Coronavirus Disease 2019 (COVID-19) Infection: A Meta-Analysis

Coronavirus disease 2019 and cardiovascular system: A narrative review

Delirium is a good predictor for poor outcomes from coronavirus disease 2019 (COVID-19) pneumonia: A systematic review, meta-analysis, and meta-regression

COVID-19 and comorbidities: a systematic review and meta-analysis

Obstructive sleep apnea (OSA) and outcomes from coronavirus disease 2019 (COVID-19) pneumonia: a systematic review and meta-analysis

Pre-admission glucagon-like peptide-1 receptor agonist (GLP-1RA) and mortality from coronavirus disease

A systematic review, meta-analysis, and meta-regression

Parkinson's disease may worsen outcomes from coronavirus disease 2019 (COVID-19) pneumonia in hospitalized patients: A systematic review, meta-analysis, and meta-regression

Human immunodeficiency virus and mortality from coronavirus disease 2019: A systematic review and meta-analysis

Epilepsy and The Risk of Severe Coronavirus Disease 2019 Outcomes: A Systematic Review, Meta-analysis, and Meta-Regression

Impact of COVID-19 pandemic on mental health in the general population: A systematic review

Cytokines dysregulation in schizophrenia: A systematic review of psychoneuroimmune relationship

Constructing the Immune Signature of Schizophrenia for Clinical Use and Research; An Integrative Review Translating J o u r n a l P r e -p r o o f Descriptives Into Diagnostics. Front Psychiatry

Income inequality and schizophrenia: increased schizophrenia incidence in countries with high levels of income inequality

Mental illness-related stigma in healthcare: Barriers to access and care and evidence-based solutions. Healthc Manage Forum

Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

Quality assessment of observational studies in a drug-safety systematic review, comparison of two tools: the Newcastle-Ottawa Scale and the RTI item bank

Operating characteristics of a rank correlation test for publication bias

Severe mental illness is associated with increased mortality and severe course of COVID-19

COVID-19 Prevalence and Mortality Among Schizophrenia Patients: A Large-Scale Retrospective Cohort Study

Increased in-hospital mortality from COVID-19 in patients with schizophrenia

Disparities in Intensive Care Unit Admission and Mortality Among Patients With Schizophrenia and COVID-19: A National Cohort Study

Association of mental disorders with SARS-CoV-2 infection and severe health outcomes: nationwide cohort study

Association of Confirmed COVID-19 Cases: Results from the PRECOVID Study in Spain

Patients with schizophrenia have decreased COVID-19 prevalence among hospitalised patients with psychiatric and neurological diseases: A retrospective analysis in Mexican population

Association between COVID-19 prognosis and disease presentation, comorbidities and chronic treatment of hospitalized patients

Predictors of survival in older adults hospitalized with COVID-19

Association Between Mental Health Disorders and Mortality Among Patients With

Countries: A Systematic Review and Meta-analysis. JAMA Psychiatry

Do patients with schizophrenia have higher infection and mortality rates due to COVID-19? A systematic review. Psychiatriki

COVID-19 in People With Schizophrenia: Potential Mechanisms Linking Schizophrenia to Poor Prognosis. Front Psychiatry

Dysregulation of Immune Response in Patients With Coronavirus

Inflammatory and hematologic markers as predictors of severe outcomes in COVID-19 infection: A systematic review and meta-analysis

Cytokine storm induced by SARS-CoV-2

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Tocilizumab administration is associated with the reduction in biomarkers of coronavirus disease 2019 infection

Meta-analysis of coagulation parameters associated with disease severity and poor prognosis of COVID-19

Clinical characteristics, hospital course, and outcomes among COVID-19 positive patients with mental illness in a community hospital in New York City

Increased risk for venous thromboembolism among patients with concurrent depressive, bipolar, and schizophrenic disorders

Psychotropic drugs and fatal pulmonary embolism

Venous Thromboembolism During Treatment with Antipsychotics: A Review of Current Evidence

Dyslipidemia is associated with severe coronavirus disease 2019 (COVID-19) infection

Proton pump inhibitor use is associated with

Dipeptidyl peptidase 4 (DPP4) inhibitor and outcome from coronavirus disease 2019 (COVID-19) in diabetic patients: a systematic review, metaanalysis, and meta-regression

Metformin use is associated with reduced mortality rate from coronavirus disease 2019 (COVID-19) infection

Medical comorbidity in schizophrenia

Clinical characteristics and mortality associated with COVID-19 in Jakarta, Indonesia: A hospitalbased retrospective cohort study

) selection of the non-exposed cohort